Literature DB >> 12488533

Chemical synthesis of MT1 and MT7 muscarinic toxins: critical role of Arg-34 in their interaction with M1 muscarinic receptor.

Gilles Mourier1, Sébastien Dutertre, Carole Fruchart-Gaillard, André Ménez, Denis Servent.   

Abstract

Two muscarinic toxins, MT1 and MT7, were obtained by one-step solid-phase synthesis using the 9-fluorenylmethoxycarbonyl-based method. The synthetic and natural toxins, isolated from the snake venom or recombinantly expressed, display identical physicochemical properties and pharmacological profiles. High protein recovery allowed us to specify the selectivity of these toxins for various muscarinic receptor subtypes. Thus, sMT7 has a selectivity for the M1 receptor that is at least 20,000 times that for the other subtypes. The stability of the toxin-receptor complexes indicates that sMT1 interacts reversibly with the M1 receptor, unlike sMT7, which binds it quasi-irreversibly. The effect of the synthetic toxins on the atropine-induced [3H]N-methylscopolamine (NMS) dissociation confirms that sMT7 targets the allosteric site on the M1 receptor, whereas sMT1 seems interact on the orthosteric one. The great decreases in the binding potencies observed after the R34A modification in sMT1 and sMT7 toxins highlight the functional role of this conserved residue in their interactions with the M1 receptor. Interestingly, after the R34A modification, the sMT7 toxin binds reversibly on the M1 receptor. Furthermore, the potency of sMT7-R34A for the NMS-occupied receptor is lower compared with unmodified toxin, supporting the role of this residue in the allosteric interaction of sMT7. All these results and the different charge distributions observed at the two toxin surfaces of their structure models support the hypothesis that the two toxins recognize the M1 receptor differently.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12488533     DOI: 10.1124/mol.63.1.26

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  18 in total

Review 1.  Functional M3 muscarinic acetylcholine receptors in mammalian hearts.

Authors:  Zhiguo Wang; Hong Shi; Huizhen Wang
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

2.  Mambalgin-1 Pain-relieving Peptide, Stepwise Solid-phase Synthesis, Crystal Structure, and Functional Domain for Acid-sensing Ion Channel 1a Inhibition.

Authors:  Gilles Mourier; Miguel Salinas; Pascal Kessler; Enrico A Stura; Mathieu Leblanc; Livia Tepshi; Thomas Besson; Sylvie Diochot; Anne Baron; Dominique Douguet; Eric Lingueglia; Denis Servent
Journal:  J Biol Chem       Date:  2015-12-17       Impact factor: 5.157

3.  Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.

Authors:  Justyna Ciolek; Helen Reinfrank; Loïc Quinton; Say Viengchareun; Enrico A Stura; Laura Vera; Sabrina Sigismeau; Bernard Mouillac; Hélène Orcel; Steve Peigneur; Jan Tytgat; Laura Droctové; Fabrice Beau; Jerome Nevoux; Marc Lombès; Gilles Mourier; Edwin De Pauw; Denis Servent; Christiane Mendre; Ralph Witzgall; Nicolas Gilles
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

4.  How three-finger-fold toxins interact with various cholinergic receptors.

Authors:  Carole Fruchart-Gaillard; Gilles Mourier; Catherine Marquer; André Ménez; Denis Servent
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

5.  Adrenoceptor activity of muscarinic toxins identified from mamba venoms.

Authors:  K Näreoja; J P Kukkonen; S Rondinelli; D M Toivola; J Meriluoto; J Näsman
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Structural model of ligand-G protein-coupled receptor (GPCR) complex based on experimental double mutant cycle data: MT7 snake toxin bound to dimeric hM1 muscarinic receptor.

Authors:  Catherine Marquer; Carole Fruchart-Gaillard; Guillaume Letellier; Elodie Marcon; Gilles Mourier; Sophie Zinn-Justin; André Ménez; Denis Servent; Bernard Gilquin
Journal:  J Biol Chem       Date:  2011-06-17       Impact factor: 5.157

7.  Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the α2-adrenoceptors.

Authors:  Céline Rouget; Loïc Quinton; Arhamatoulaye Maïga; Céline Gales; Geoffrey Masuyer; Christian Malosse; Julia Chamot-Rooke; Robert Thai; Gilles Mourier; Edwin De Pauw; Nicolas Gilles; Denis Servent
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

8.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

9.  Molecular conversion of muscarinic acetylcholine receptor M(5) to muscarinic toxin 7 (MT7)-binding protein.

Authors:  Sergio Rondinelli; Katja Näreoja; Johnny Näsman
Journal:  Toxins (Basel)       Date:  2011-11-11       Impact factor: 4.546

10.  Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.

Authors:  Arhamatoulaye Maïga; Jon Merlin; Elodie Marcon; Céline Rouget; Maud Larregola; Bernard Gilquin; Carole Fruchart-Gaillard; Evelyne Lajeunesse; Charles Marchetti; Alain Lorphelin; Laurent Bellanger; Roger J Summers; Dana S Hutchinson; Bronwyn A Evans; Denis Servent; Nicolas Gilles
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.